Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
50
CHGCF Quote, Financials, Valuation and Earnings
Last price:
$55.44
Seasonality move
:
0.48%
Day range:
$50.98 - $55.44
52-week range:
$32.25 - $72.30
Dividend yield:
1.27%
P/E ratio:
34.23x
P/S ratio:
11.21x
P/B ratio:
7.13x
Volume:
874
Avg. volume:
2.2K
1-year change:
32.79%
Market cap:
$91.2B
Revenue:
$7.7B
EPS (TTM):
$1.62
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CHGCF
Chugai Pharmaceutical Co., Ltd.
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 3.82% | -- | $17.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CHGCF
Chugai Pharmaceutical Co., Ltd.
|
$55.44 | -- | $91.2B | 34.23x | $0.86 | 1.27% | 11.21x |
|
PPTDF
PeptiDream Inc.
|
$11.98 | -- | $1.5B | 13.79x | $0.00 | 0% | 12.90x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.08 | -- | $459.3M | -- | $0.00 | 0% | 2.37x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$15.58 | $17.93 | $49.2B | 197.72x | $0.32 | 4.24% | 1.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CHGCF
Chugai Pharmaceutical Co., Ltd.
|
0.64% | -0.884 | 0.12% | 4.62x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CHGCF
Chugai Pharmaceutical Co., Ltd.
|
$1.6B | $1.2B | 20.71% | 20.83% | 53.77% | $396.5M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
Chugai Pharmaceutical Co., Ltd. vs. Competitors
-
Which has Higher Returns CHGCF or PPTDF?
PeptiDream Inc. has a net margin of 33.38% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -25.38%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 20.83% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital CHGCFChugai Pharmaceutical Co., Ltd.69.91% $0.46 $12.9B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About CHGCF or PPTDF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHGCFChugai Pharmaceutical Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is CHGCF or PPTDF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of -0.088, which suggesting that the stock is 108.831% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock CHGCF or PPTDF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.86 per share corresponding to a yield of 1.27%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 41.63% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCF or PPTDF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.3B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Chugai Pharmaceutical Co., Ltd.'s net income of $754.1M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 34.23x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 11.21x versus 12.90x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCFChugai Pharmaceutical Co., Ltd.11.21x 34.23x $2.3B $754.1M PPTDFPeptiDream Inc.12.90x 13.79x $29.3M -$7.4M
-
Which has Higher Returns CHGCF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 33.38% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -24.76%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 20.83% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital CHGCFChugai Pharmaceutical Co., Ltd.69.91% $0.46 $12.9B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About CHGCF or SOLTF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHGCFChugai Pharmaceutical Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is CHGCF or SOLTF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of -0.088, which suggesting that the stock is 108.831% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock CHGCF or SOLTF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.86 per share corresponding to a yield of 1.27%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 41.63% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCF or SOLTF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.3B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Chugai Pharmaceutical Co., Ltd.'s net income of $754.1M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 34.23x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 11.21x versus 2.37x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCFChugai Pharmaceutical Co., Ltd.11.21x 34.23x $2.3B $754.1M SOLTFNxera Pharma Co., Ltd.2.37x -- $45.8M -$11.3M
-
Which has Higher Returns CHGCF or STMM?
Stemcell Holdings, Inc. has a net margin of 33.38% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of --. Chugai Pharmaceutical Co., Ltd.'s return on equity of 20.83% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CHGCFChugai Pharmaceutical Co., Ltd.69.91% $0.46 $12.9B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About CHGCF or STMM?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHGCFChugai Pharmaceutical Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is CHGCF or STMM More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of -0.088, which suggesting that the stock is 108.831% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CHGCF or STMM?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.86 per share corresponding to a yield of 1.27%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 41.63% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCF or STMM?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.3B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Chugai Pharmaceutical Co., Ltd.'s net income of $754.1M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 34.23x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 11.21x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCFChugai Pharmaceutical Co., Ltd.11.21x 34.23x $2.3B $754.1M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns CHGCF or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 33.38% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -1.05%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 20.83% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital CHGCFChugai Pharmaceutical Co., Ltd.69.91% $0.46 $12.9B TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About CHGCF or TAK?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 14.94%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Chugai Pharmaceutical Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Chugai Pharmaceutical Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHGCFChugai Pharmaceutical Co., Ltd.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is CHGCF or TAK More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of -0.088, which suggesting that the stock is 108.831% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock CHGCF or TAK?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.86 per share corresponding to a yield of 1.27%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.24% to investors and pays a quarterly dividend of $0.32 per share. Chugai Pharmaceutical Co., Ltd. pays 41.63% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios CHGCF or TAK?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.3B, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Chugai Pharmaceutical Co., Ltd.'s net income of $754.1M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 34.23x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 197.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 11.21x versus 1.68x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCFChugai Pharmaceutical Co., Ltd.11.21x 34.23x $2.3B $754.1M TAKTakeda Pharmaceutical Co., Ltd.1.68x 197.72x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
